Clinical trials are a key tool to advance in the development of new treatments and achieve more accurate diagnoses. The Vall d'Hebron Campus, of which the Vall d'Hebron Institute of Research (VHIR) is part, consolidates its position as an international reference centre in this field.

During 2024, VHIR has managed a total of 1,029 clinical studies, of which 681 are clinical trials covering all phases: 47 in phase I, 226 in phase II, 351 in phase III and 57 in phase IV, with more than 40% of the studies located in early phases, essential for the validation of the safety and efficacy of new drugs and therapeutic approaches. In total, 169 new clinical trials have been initiated, a figure that reflects the centre's sustained activity in clinical research.

One of the great strengths of the VHIR is its commitment to particularly sensitive areas with research needs, such as minority diseases, with 208 clinical trials dedicated to these pathologies of low or very low prevalence, and paediatric research, with 192 ongoing trials aimed at the paediatric and adolescent population. Also noteworthy is the boost in advanced therapies, with 31 active clinical trials.

Throughout 2024, 638 patients have decided to collaborate and participate in VHIR clinical trials. This participation of patients and volunteers is essential to advance research and bring innovative treatments to the public that can change the quality of life of many people. In fact, the active participation of patients and families in studies helps to identify more effective therapies that improve quality of life and survival.

The clinical research of VHIR in paediatric and adult settings

At VHIR, clinical trials are promoted at all stages of life. In both paediatrics and adults, the aim of these studies is to offer new therapeutic options that are safe and effective for each patient.

In adulthood, in 2024, the results of a clinical trial were published showing the potential of probiotics and prebiotics to control the irritability associated with ADHD and borderline personality disorder. In addition, the Nephrology and Renal Transplantation group participated in a study on a new treatment for resistant hypertension, a key risk factor for heart disease. In geriatrics, the clinical trial of the PROFIT project has shown the benefits of personalised physical exercise for elderly cancer patients.

VHIR has also participated in several paediatric trials, for example to study the treatment with ruxolitinib in patients with acute host immune system disease, or to demonstrate the efficacy of gene therapy in patients with Fanconi's anaemia. Recently, the BRIDGE project has been launched, which introduces a new, more digital, collaborative and inclusive approach to facilitate the participation of more children in clinical trials and improve access to innovative therapies.